Conectus
TRANSPEP

Picto Conectus
2013
Health (therapeutic and diagnosis)
Health (therapeutic and diagnosis)

TRANSPEP

How to develop a cancer therapy

Project description

This project involves the validation of a novel peptide compound (MTP-NRP1) anti-tumor. 

Why does Conectus invest in this project?

Conectus' financial investment will make it possible to carry out studies for the production of a GMP (Good Manufacturing Practice) quality peptide and to find the best combination of treatments to refine the market positioning of targeted cancer therapies.

At the origin of the project:

Dominique Bagnard, (Senior Lecturer - MN3T Laboratory (The Microenvironmental Niche in Tumorigenesis and Targeted Therapy)

Focus

Conectus is investing in this project: 304 290 €.
Duration: 18 months

Back to the project list
Do you really want to remove this technology from your list ?
close